Recent News

• 03.11.2025 - Barclays Global Healthcare Conference
• 03.10.2025 - Leerink Partners Global Biopharma Conference
• 03.10.2025 - BEAM-302 Initial Clinical Data Investor Webcast
• 03.10.2025 - Beam Therapeutics Announces Pricing of Underwritten Offering
• 03.10.2025 - Beam Therapeutics Announces Pricing of Underwritten Offering
• 03.10.2025 - Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
• 03.10.2025 - Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.25.2025 - Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
• 02.25.2025 - Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Recent Filings

• 02.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.25.2025 - 8-K Current report
• 02.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2025 - EX-99.1 EX-99.1
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 144 Report of proposed sale of securities